OptiNose’s innovative approach enables broad, consistent drug delivery deep in the nasal cavity, leveraging the mucosal surfaces as a potent target for the treatment of both local and systemic diseases. Known as Bi-Directional™ Breath Powered® technology, the OptiNose platform offers a much-needed alternative to traditional nasal inhalers, as well as to tablets and injections. LEARN MORE »
See how it works
OptiNose’s late-stage candidates include OPN-375 and AVP-825 to treat Chronic Nasal Inflammatory Diseases and migraine, respectively. We have also identified more than ten pipeline candidates that we believe hold outstanding potential to solve currently intractable treatment challenges with our Bi-Directional Breath Powered technology. VIEW CANDIDATES »
News & Media Coverage
February 01, 2016 | News
OptiNose® Announces Pipeline Project to Evaluate Nose-to-Brain Application of Bi-Directional™ Bre...
January 28, 2016 | News
OptiNose Announces FDA Approval for ONZETRA™ Xsail™ (sumatriptan nasal powder), a New Treatment ...
December 17, 2015 | News
OptiNose to Present at the 34th Annual J.P. Morgan Healthcare Conference